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Abstract
Aims/hypothesis The renal and cardiovascular protective
effects of angiotensin receptor blocker (ARB) remain
controversial in type 2 diabetic patients treated with a
contemporary regimen including an angiotensin converting
enzyme inhibitor (ACEI).
Methods We examined the effects of olmesartan, an ARB,
on primary composite outcome of doubling of serum
creatinine, endstage renal disease and death in type 2
diabetic patients with overt nephropathy. Secondary out-
come included composite cardiovascular outcomes,
changes in renal function and proteinuria. Randomisation
and allocation to trial group were carried out by a central
computer system. Participants, caregivers, the people
carrying out examinations and people assessing the out-
comes were blinded to group assignment.
Results Five hundred and seventy-seven (377 Japanese,
200 Chinese) patients treated with antihypertensive therapy
(73.5% [n=424] received concomitant ACEI), were given
either once-daily olmesartan (10–40 mg) (n=288) or
placebo (n=289) over 3.2±0.6 years (mean±SD). In the
olmesartan group, 116 developed the primary outcome
(41.1%) compared with 129 (45.4%) in the placebo group
(HR 0.97, 95% CI 0.75, 1.24; p=0.791). Olmesartan
significantly decreased blood pressure, proteinuria and rate
of change of reciprocal serum creatinine. Cardiovascular
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death was higher in the olmesartan group than the placebo
group (ten vs three cases), whereas major adverse cardio-
vascular events (cardiovascular death plus non-fatal stroke
and myocardial infarction) and all-cause death were similar
between the two groups (major adverse cardiovascular
events 18 vs 21 cases, all-cause deaths; 19 vs 20 cases).
Hyperkalaemia was more frequent in the olmesartan group
than the placebo group (9.2% vs 5.3%).
Conclusions/interpretation Olmesartan was well tolerated
but did not improve renal outcome on top of ACEI.
Trial registration: ClinicalTrials.gov NCT00141453
Funding: The ORIENT study was supported by a research
grant from Daiichi Sankyo.
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Abbreviations
ACEI Angiotensin-converting enzyme inhibitors
ARB Angiotensin II receptor blocker
CVD Cardiovascular disease
ESRD Endstage renal disease
HF Heart failure
IDMC Independent data monitoring committee
IDNT Irbesartan Type II Diabetic Nephropathy Trial
MI Myocardial infarction
ORIENT Olmesartan Reducing Incidence of End stage
renal disease in diabetic Nephropathy Trial
RENAAL Reduction of Endpoints in NIDDM with the
Angiotensin II Antagonist Losartan
SCr Serum creatinine
TIA Transient ischaemic attack
UACR Urinary albumin/creatinine ratio
Introduction
In this global epidemic of diabetes, 60% of affected people
come from Asia. Approximately 10% of adults in Japan [1]
and Hong Kong [2] have diabetes. Diabetic complications
cause premature death and disabilities with reduced
productivity and high healthcare costs [3]. Type 2 diabetes
is the leading cause of endstage renal disease (ESRD)
worldwide [4]. Annually, 15,000 Japanese develop ESRD
due to diabetes [5]. In Hong Kong with 6.7 million
southern Chinese, 4,268 patients received renal replacement
therapy in 1999, that is 627 patients per million [6].
Glycaemic [7] and BP [8] control have been shown to
reduce proteinuria and slow decline of renal function. In
two landmark studies of type 2 diabetic nephropathy
(Reduction of Endpoints in NIDDM with the Angiotensin
II Antagonist Losartan (RENAAL) [9] and Irbesartan Type
II Diabetic Nephropathy Trial (IDNT) [10]), treatment with
angiotensin II receptor blockers (ARB) reduced proteinuria,
slowed decline of renal function and reduced incidence
of ESRD. In the RENAAL subgroup analysis including
17% of its participants of Asian ethnicity, ARB reduced
risk of renal outcomes by 35% in Asians [11] and 45%
in Japanese [12] compared with 16% in the whole cohort.
Despite the high risk of East Asians for diabetic kidney
disease, they often tolerate angiotensin-converting enzyme
inhibitors (ACEI) poorly due to cough [13]. Furthermore,
there are ongoing concerns regarding the risk–benefit
ratio of dual therapy with ARB and ACEI in high-risk
patients [14].
Objectives
In this randomised, placebo-controlled, multicentre clinical
trial named ORIENT (Olmesartan Reducing Incidence of
Endstage Renal Disease in Diabetic Nephropathy Trial), we
examined the renoprotective benefits of olmesartan medox-
omil, an ARB, using the composite endpoint of time to the
first occurrence of doubling of serum creatinine (SCr),
ESRD and death, mostly in the presence of ACEI
therapy. The safety of olmesartan and its effect on renal
function, proteinuria and cardiovascular outcome was
also evaluated.
Methods
Participants The study design was in line with the CONSORT
statement [15] and conducted in good clinical practice by
experts in nephrology and endocrinology. The study design
has previously been described [16]. We enrolled type 2
diabetic patients from Japan and Hong Kong with the
following inclusion criteria: (1) age between 30 and 70 years;
(2) urinary albumin/creatinine ratio (UACR) >33.9 mg/mmol
(>300 mg/g) in the first morning urine sample; (3) serum
creatinine (SCr) concentration of 88.40–221.00 μmol/l (1.0–
2.5 mg/dl) in women and 106.08–221.00 μmol/l (1.2–2.5 mg/
dl) in men. Major exclusion criteria included: (1) type 1
diabetes; (2) history of myocardial infarction (MI) or coronary
artery bypass grafting (CABG) within 3 months prior to
consent; (3) percutaneous coronary intervention, carotid artery
or peripheral artery revascularisation within 6 months; (4)
stroke or transient ischaemic attack (TIA) within 1 year; (5)
unstable angina pectoris or heart failure (HF) of New York
Heart Association functional class III or IV; (6) rapidly
progressive renal disease within 3 months prior to consent; (7)
severe orthostatic hypotension; and (8) serum potassium level
≤3.5 mmol/l or ≥5.5 mmol/l.
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Study design, governance and implementation The trial
commenced in 2003 and was approved by the institutional
ethics committee concerned. All patients provided written
informed consent. In Hong Kong, all patients were treated
with ACEI. In 2006 when losartan was approved for use in
type 2 diabetic nephropathy with hypertension by the
Japanese Ministry of Health, Labor and Welfare, we re-
obtained a written informed consent from each patient in
Japan to continue to participate in the study. The study was
governed by a steering committee, an independent data
monitoring committee (IDMC) and an endpoint adjudica-
tion committee, all consisting of academics and clinicians
independent of the sponsor. The steering committee
provided guidance for the overall study design, conduct of
the trial, data management and analysis. The endpoint
adjudication committee evaluated and classified the primary
and secondary outcomes under blinded conditions.
The source data included case report forms, hospital records
and laboratory data (e.g. biomarkers, electrocardiogram,
images of computerised tomography [CT] scans and MRI).
For each specialty (cardiology, neurology and nephrology), two
or three experts independently classified all clinical endpoints.
An IDMC comprising a nephrologist, a diabetologist and a
statistician, independently monitored the trial for safety and
ethical issues with access to assigned codes as indicated. The
IDMCwas able to discontinue the entire study if an unusually
high number of participants developed unexpected severe
adverse events or in the unlikely event that unblinding was
indicated for clinical decision making. During the entire study
period, none of the treatment codes have been unblinded.
Daiichi Sankyo monitored the implementation of the trial,
validated all source data and performed the analysis as guided
by the steering committee. All members of the steering
committee had full access to data and prepared the final
manuscript. The protocol was approved by regulatory
authorities and the ethics review committee at each partici-
pating institution.
Interventions During the initial 6-week screening period,
patients were treated with placebo and assessed for
inclusion and exclusion criteria. Eligible patients were
randomly assigned to receive either 10 mg of olmesartan
once-daily or placebo. If the target BP of <130/85 mmHg
was not achieved 4 weeks after randomisation or at any
time thereafter, the dose of olmesartan was increased to
20 mg daily (or placebo), with further titration to 40 mg (or
placebo), if necessary, upon which additional antihyperten-
sive agents could be used. These included diuretics,
β blockers, calcium channel blockers and α blockers. Every
reasonable attempt was made to up-titrate the test drug to the
maximum dose, even if target BP was achieved. Use of
potassium-sparing diuretics or ARB was prohibited, and
addition of ACEI after enrolment was not allowed. Patients
treated with ACEI at baseline must continue with the same
dosage throughout the study.
Study outcomes and definitions All patients visited the
clinic at 2, 4, 8 and 12 weeks, and then returned every
12 weeks throughout the study duration. At each visit, BP
was measured and clinical samples were collected for
measurement of urinary protein/creatinine ratio and serum
levels of creatinine and potassium. All randomised patients
including those discontinued from the study for any reason
other than death were followed up for ascertainment of
primary and secondary endpoints until termination of study.
The efficacy measure was the time to the first event of
the primary composite outcome of doubling of SCr, ESRD
(SCr >442.01 μmol/l [5 mg/dl]), chronic dialysis, trans-
plantation and all-cause death. SCr was measured at a
central laboratory in Japan (SRL, Tokyo, Japan). The
secondary composite outcome included: (1) a composite
endpoint of first occurrence of any of the following events:
cardiovascular death, non-fatal stroke except for TIAs, non-
fatal MI, hospitalisation for unstable angina, hospitalisation
for HF, revascularisation of coronary, carotid or peripheral
arteries, lower extremity amputation; (2) change in protein-
uria; (3) rate of decline of SCr reciprocal (1/SCr).
Randomisation and blinding After written informed consent
was obtained and following the run-in period, eligible patients
were randomised into olmesartan group or placebo group by
the registration centre in Japan (EPS, Tokyo, Japan) through
fax contact. The centre assigned each patient by the dynamic
allocation method, depending on whether or not they were
using ACEIs, further stratified by UACR and SCr. The
proportion of patients included in each category was similar
between the olmesartan and placebo groups.
All persons involved in the study were unaware of the
drug assignments, except for the person in charge of drug
assignment who was not involved in the study. The IDMC
examined the data in a blinded fashion, except for serious
adverse events for which a causal relationship with the
study drug cannot be ruled out.
Sample-size estimation We assumed the primary endpoint
in this study, defined as the composite renal event rate, to
be 0.583 events/patient during an average 4-year follow-up
period in the placebo group. The assumed event rate was
calculated based on the results from Japanese patients in the
RENAAL Study [11] (event rate, 34/52=0.654 with an
average follow-up period of 3.4 years). We assumed a 30%
risk reduction with baseline ACEI treatment [17]. Therefore,
the event rate of the placebo group with baseline ACEI
treatment was estimated to be 0.583 with an average follow-
up period of 4 years. On the other hand, the event rate of the
olmesartan group with ACEI treatment was assumed to be
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0.434, as we hypothesised an additional 35% risk reduction
in the olmesartan group compared with the placebo group.
Based on these assumptions, 172 patients were needed in
each treatment group to detect a statistically significant
difference between treatment groups using the logrank test
with α=0.05 (two-sided) and 1−β=0.80. Assuming that
fewer than 15% of patients would be lost to follow-up, the
number of patients was determined to be 200 per group.
Statistical analysis All analyses of the outcomes were
conducted under the intention-to-treat principle. The Cox
regression model was applied to estimate the HR between
treatment groups with 95% CI for the renal and cardiovas-
cular composite event rates [18]. The covariates in the
model selected based on review of blinded data were (1)
UACR and SCr at baseline and regions (Japan/Hong Kong)
for the renal composite event rate, and (2) baseline UACR
and age for cardiovascular composite event rate.
After unblinding, approximately twofold more patients
assigned to the olmesartan group were found to have
history of cardiovascular disease (CVD) than in the placebo
group (60 in olmesartan group vs 33 in placebo group,
Table 1), which was a strong prognostic factor for
cardiovascular outcome. Thus, this variable was included
as an additional covariate in the model of composite
cardiovascular event rate. We also adjusted for BP differ-
ences between the two groups by including the mean
arterial pressure during treatment as a time-dependent
covariate in the Cox model for composite event rates. The
Kaplan–Meier method was used to estimate the cumulative
event rate by treatment groups [19].
The linear mixed effect model was used to compare the
trend in the percentage change of urinary protein/creatinine
ratio and trend in the change in 1/SCr between treatment
groups. Consistency of treatment effects in prespecified
subgroups was explored by Cox regression model with tests
for interaction. Serious adverse events and discontinuation of
the study drug due to adverse event were summarised. All
statistical tests were two-sided with 0.05 significance level.
Statistical analyses were performed using SAS version 8.2.
Results
Patients From May 2003 to July 2005, 857 type 2 diabetic
patients were screened at 74 centres in Japan and three
centres in Hong Kong with a final enrolment of 577
patients (377 Japanese and 200 Chinese) (Electronic
supplementary material [ESM] Fig. 1). Eligible patients
were randomised to receive either olmesartan or placebo
using a central allocation system based in Japan. We stopped
the study early in February 2008 according to the recommen-
dation of the IDMC, which indicated that the primary renal
events had reached the expected rate. Eleven patients were
excluded from the final analysis due to protocol violation from
the viewpoint of good clinical practice. Amongst the analysed
patients (n=566), 282 received olmesartan and 284 received
placebo in addition to conventional antihypertensive therapy.
Of these, 414 (73.1%) patients treated with ACEI continued
with the same dosage throughout the study period, which
lasted 3.2 (0.6)years (mean [SD]). Both groups had similar
clinical profiles except for a higher percentage of CVD in the
olmesartan group (Table 1).
BP At baseline, 93.8% of patients were receiving antihy-
pertensive treatment (Table 1). In the olmesartan group, BP
fell from 141.7/77.8 mmHg at baseline to 137.5/75.1 mmHg
at week 12 and to 131.8/72.2 mmHg at week 144. In the
placebo group, BP fell from 140.8/77.2 mmHg to 140.3/
76.6 mmHg at week 12 and to 136.6/73.6 mmHg at week 144
(ESM Fig. 2). Time-averaged differences of systolic and
diastolic BP between the olmesartan and placebo groups
were 2.8 (1.0) mmHg and 1.6 (0.6) mmHg, respectively (p<
0.01). The daily dose of olmesartan ranged from 10 to
40 mg, with 49.1%, 60.3% and 63.4% of patients receiving
40 mg at weeks 12, 48 and 144, respectively.
Primary outcome The primary composite outcome oc-
curred in 116 patients in the olmesartan group (41.1%)
and 129 patients in the placebo group (45.4%) (Fig. 1). The
HR for primary renal composite outcome in the olmesartan
group was 0.97 (0.75, 1.24; p=0.791) with HR 1.02 (0.79,
1.32; p=0.852) after adjustment for BP (Table 2). The
neutral effect of treatment was consistent across all
prespecified subgroups.
Secondary outcome The composite secondary cardiovascular
outcome occurred in 40 olmesartan-treated patients (14.2%)
and 53 placebo-treated patients (18.7%) with HR 0.73 (0.48,
1.09; p=0.126) (Fig. 2). In a post hoc analysis, HR was
decreased to 0.64 (0.43, 0.98; p=0.039) after adjusting for
unbalanced distribution of history of CVD at baseline
(Table 3). HR was changed little after adjusting for BP (0.66
[0.43, 1.00; p=0.049]). The HR in cardiovascular outcome
was consistent in patients treated with or without ACEI.
In the placebo group with a baseline value of proteinuria
of 231.9 mg/mmol Cr, median percentage changes from
baseline were +12.6% at week 12, +6.9% at week 48 and
−3.1% at week 144. In the olmesartan group with a baseline
value of proteinuria of 247.7 mg/mmol Cr, the
corresponding figures were −19.5% at week 12, −20.0%
at week 48 and −24.9% at week 144 (Fig. 3, p=0.005). The
trend in the change in 1/SCr was different between the
treatment and placebo groups (p<0.001). The median
yearly rate of change of 1/SCr was −0.933 (interquartile
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range (IQR) −1.934 to −0.419) l mmol−1 year−1 in the
olmesartan and −1.164 (IQR −1.976 to −0.575)
l mmol−1 year−1 in the placebo group (Fig. 4). We further
categorised patients by their median 1/SCr slope. In patients
with accelerated rate of decline of renal function who had
1/SCr slope greater than the median, the slope in
olmesartan-treated patients overlapped with the placebo
(Fig. 4). More than 90% of renal outcomes occurred in
patients with steep slope of 1/SCr who had higher BP and
heavier proteinuria at baseline than those with less
accelerated rate of decline of 1/SCr.
Safety Serious adverse events occurred in 146 olmesartan-
treated patients (51.8%) and 169 placebo-treated patients
Table 1 Baseline characteristics
of type 2 diabetic patients with




inhibitor randomised to receive
either olmesartan or placebo
treatment for a mean period of
3.2 years
Data are means±SD, n (%) or
median (interquartile range)
Characteristics Olmesartan (n=282) Placebo (n=284)
Age (years) 59.1±8.1 59.2±8.1
Japanese/Chinese, n 182:100 184:100
Male sex, n (%) 199 (70.6) 192 (67.6)
Smoker, n (%) 72 (25.5) 72 (25.4)
Weight (kg) 66.7±13.6 66.1±12.0
Body mass index (kg/m2) 25.3±4.2 25.3±3.8
Systolic blood pressure (mmHg) 141.7±17.0 140.8±18.0
Diastolic blood pressure (mmHg) 77.8±10.4 77.2±10.6
UACR (mg/mmol) 192.3 (87.1–339.4) 191.2 (98.4–352.9)
Urinary protein/creatinine ratio (mg/mmol) 247.7 (112.0–437.8) 231.9 (124.4–429.9)
Serum creatinine (μmol/l) 143.21±28.29 143.21±30.94




Total cholesterol (mmol/l) 5.41±1.38 5.36±1.18
Blood haemoglobin (g/l) 124±20 121±19
Uric acid (mmol/l) 434.24±95.18 428.29±89.23
Medical history, n (%)
Diabetic retinopathy 228 (80.9) 233 (82.0)
Diabetic neuropathy 144 (51.1) 154 (54.2)
Cardiovascular disease 60 (21.3) 33 (11.6)
MI 11 (3.9) 5 (1.8)
Coronary revascularisation 24 (8.5) 8 (2.8)
HF 12 (4.3) 9 (3.2)
Peripheral arterial disease 33 (11.7) 19 (6.7)
Stroke or TIA 41 (14.5) 42 (14.8)
Severe orthostatic hypotension 3 (1.1) 5 (1.8)
Medications, n (%)
Insulin 139 (49.3) 153 (53.9)
Oral glucose-lowering drugs 165 (58.5) 175 (61.6)
Lipid regulating drugs 155 (55.0) 149 (52.5)
Erythropoietin 10 (3.5) 6 (2.1)
Aspirin 58 (20.6) 55 (19.4)
Antihypertensive agents 262 (92.9) 269 (94.7)
Diuretics 108 (38.3) 99 (34.9)
Calcium channel blockers 186 (66.0) 198 (69.7)
ACEI 205 (72.7) 209 (73.6)
α Blockers 41 (14.5) 41 (14.4)
β Blockers 54 (19.1) 42 (14.8)
Others 37 (13.1) 38 (13.4)
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(59.5%). In total, 73 (25.9%) olmesartan-treated patients
and 64 (22.5%) placebo-treated patients were discontinued
before study completion due to adverse events (ESM
Table 1). Cardiovascular death was higher in the olmesartan
group than the placebo group (ten vs three cases), whereas
major adverse cardiovascular events (cardiovascular death
plus non-fatal stroke and MI) and all-cause death were
similar between the two groups (major adverse cardiovas-
cular events 18 vs 21 cases, all-cause deaths; 19 vs 20
cases). Discontinuation rate due to hyperkalaemia was
higher in the olmesartan group than the placebo group (26
[9.2%] vs 15 [5.3%]). The respective rates were 11.7% vs
7.2% in the ACEI-treated patients and 2.6% vs 0% in the
non-ACEI-treated patients. None of the patients required
acute dialysis in the first 6 months of the study, and only
one patient (0.4%) in each group was discontinued due to
acute renal failure during the study period.
Discussion
In this study, we enrolled Asian patients with clinical
profiles comparable to those in RENAAL, with the majority
of them receiving ACEI, and treated them intensively with
contemporary regimen targeting a BP <130/85 mmHg. This
was compared with a mean systolic BP of >140 mmHg
during the entire study period of RENAAL. Although the
end-of-study BP was similar between the olmesartan and
placebo groups, there was a difference of 2.8 mmHg in
systolic BP and 1.6 mmHg in diastolic BP during the
treatment period, in favour of olmesartan. After 3.2 years,
treatment with olmesartan reduced proteinuria and slowed
decline of renal function after adjustment for BP differ-
ences. However, HR of composite renal outcome was 1.02
after adjustment for BP, suggesting that olmesartan did not
provide additional beneficial effect on renal outcome.
Although olmesartan did not reduce cardiovascular out-
come adjusted by prespecified SCr and UACR, it reduced
risk of cardiovascular outcomes by 34% independent of
ACEI treatment after further adjustment for BP and
imbalanced distribution of history of CVD at baseline
between the two groups in a post hoc analysis.
Renal effects of olmesartan The participants of ORIENT
had near optimal BP, serum cholesterol and glycaemic
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Fig. 2 Kaplan–Meier analysis of the time to secondary composite
cardiovascular endpoint in type 2 diabetic patients with overt
proteinuria and renal insufficiency. Solid line, olmesartan; dashed
line, placebo













6 12 18 24 30 36 42 48 54
Olmesartan 282 278 259 238 217 184 107 44 17
Placebo 284 279 259 236 211 176 102 41 17
Fig. 1 Kaplan–Meier analysis of the time to primary composite renal
endpoint in type 2 diabetic patients with overt proteinuria and renal
insufficiency. Solid line, olmesartan; dashed line, placebo
Table 2 HR of primary
composite renal outcome in type
2 diabetic patients with overt
proteinuria and renal
insufficiency treated with
olmesartan or matching placebo
during a 3.2 year study period
†p=0.791
Outcome n (%) Olmesartan vs placebo
Olmesartan Placebo HR (95% CI) (covariates:
SCr, ACR and region)
All patients group (olmesartan n=282, placebo n=284)
Renal composite outcome 116 (41.1) 129 (45.4) 0.97 (0.75, 1.24)†
Doubling of SCr 106 (37.6) 120 (42.3) 0.94 (0.73, 1.23)
ESRD 74 (26.2) 78 (27.5) 1.08 (0.78, 1.49)
Death from any cause 19 (6.7) 20 (7.0) 0.99 (0.53, 1.86)
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Baseline HbA1c of patients in ORIENT and RENAAL were
7.1% (57.0 mmol/mol) and 8.5% (69.4 mmol/mol), respec-
tively. Baseline total cholesterol and mean systolic BP were
lower by 19.7 mg/dl (0.51 mmol/l) and 12 mmHg in
ORIENT compared with RENAAL patients [20]. Despite
near optimal management of risk factors and use of ACEI
in most patients, treatment with olmesartan further attenu-
ated proteinuria and slowed decline of renal function
estimated by 1/SCr compared with placebo. These benefi-
cial renal effects of olmesartan were in agreement with
previous findings [21–25]. Despite these favourable renal
responses, olmesartan did not reduce the composite renal
endpoint in the whole group. On subgroup analysis, the
majority of renal endpoint occurred in patients with
accelerated decline in renal function in whom treatment
with olmesartan was similar to placebo. Taken together,
these findings suggest that treatment with olmesartan did
not confer additional renoprotection especially in patients
with rapidly declining renal function, although its effects in
patients with less severe renal impairment require further
exploration.
Cardiovascular effects of olmesartan In the primary anal-
ysis, we were unable to confirm the cardiovascular
protective effects of olmesartan, which was a predefined
secondary endpoint. Although olmesartan-treated patients
had numerically fewer MACE (cardiovascular death plus
non-fatal stroke and MI) than the placebo group (18 vs 21
cases), our study did not have sufficient power to conclude
the effects of olmesartan on cardiovascular outcomes. The
amputations that occurred in the olmesartan group were
limited to toes.
Clinical trials that examined cardiovascular protective





















Slope of 1/SCr ( l mmol−1 year−1)
Fig. 4 Cumulative frequency distribution of yearly rate of change of
1/SCr. The two arrows refer to the median values in the placebo or
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Fig. 3 Changes in proteinuria expressed as percentage change of
urinary protein/creatinine ratio from baseline during treatment with
olmesartan or placebo in type 2 diabetic patients with overt proteinuria
and renal insufficiency. Solid line, black circles, olmesartan; dashed
line, white circles, placebo. p=0.005
Table 3 HR of secondary composite cardiovascular outcomes in type 2 diabetic patients with overt proteinuria and renal insufficiency treated
with olmesartan or matching placebo during a 3.2 year study period
Outcome n (%) Olmesartan vs placebo
Olmesartan Placebo HR (95% CI) (covariates:
ACR and age)
Adjusted HR (95% CI) (covariates:
ACR, age and cardiovascular history)
All patients group (olmesartan n=282, placebo n=284)
Cardiovascular composite outcome 40 (14.2) 53 (18.7) 0.73 (0.48, 1.09)† 0.64 (0.43, 0.98)‡
Cardiovascular death 10 (3.5) 3 (1.1) 3.38 (0.93, 12.29) 2.81 (0.76, 10.38)
Non-fatal stroke 8 (2.8) 11 (3.9) 0.73 (0.29, 1.82) 0.73 (0.29, 1.83)
Non-fatal myocardial infarction 3 (1.1) 7 (2.5) 0.43 (0.11, 1.66) 0.45 (0.11, 1.75)
Hospitalisation with unstable angina 5 (1.8) 3 (1.1) 1.67 (0.40, 6.98) 1.37 (0.31, 6.00)
Hospitalisation with heart failure 18 (6.4) 25 (8.8) 0.71 (0.39, 1.30) 0.59 (0.32, 1.10)
Coronary, carotid or peripheral revascularisation 8 (2.8) 21 (7.4) 0.37 (0.16, 0.84) 0.35 (0.15, 0.80)
Amputation 4 (1.4) 0 (0.0) – (–) – (–)
† p=0.126, ‡ p=0.039
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yielded inconsistent results. In the Ongoing Telmisartan
Alone and in Combination With Ramipril Global Endpoint
Trial (ONTARGET) [26] and the Valsartan in Acute
Myocardial Infarction (VALIANT) [27], combination of
ACEI and ARB showed neutral effect compared with ACEI
alone. In the VAL-HeFT (Valsartan Heart Failure Trial) [28]
and the Candesartan in Heart Failure-Assessment of
Reduction in Mortality and Morbidity (CHARM)-added
[29], a combination of ACEI and ARB was superior to
ACEI alone. However, all these studies enrolled only a
small number of patients with overt diabetic nephropathy.
In RENAAL, which included only type 2 diabetic patients
with overt nephropathy [9], losartan alone reduced HF and
marginally reduced MI rate. In IDNT [10], irbesartan alone
did not confer cardiovascular protection compared with
placebo or amlodipine. Taken together, although our results
may support possible cardiovascular benefits of combined
therapy of ARB and ACEI in type 2 diabetic patients with
overt proteinuria and moderate renal insufficiency, larger
randomised clinical studies will be needed to confirm these
findings.
Safety of olmesartan in patients treated with ACEI Patients
in ORIENT had frequent hospitalisations with similar rates
between the two groups. Approximately 20% of patients
had premature discontinuation due to adverse events with a
higher rate of hyperkalaemia in the olmesartan than the
placebo group (9.2% vs 5.3%). There were ten cardiovas-
cular deaths (3.5%) in the olmesartan group and three
(1.1%) in the placebo group, but none of these adverse
events were related to hyperkalaemia. Considering the
similar number of all-cause deaths (19 [6.7%] in olmesartan
vs 20 [7.0%] in placebo) in both groups, the excess
cardiovascular death in the olmesartan group was attributed
to the twofold higher rate of past history of CVD in the
olmesartan group. The rates of MACE were similar between
the two groups, with a tendency of lower cardiovascular
outcome rates in the olmesartan group. None of the enrolled
patients required acute dialysis in the first 6 months of the
study, and only one patient (0.4%) in each group developed
acute renal failure during the study period.
Limitations The study has several limitations. First, there
was an imbalance of preexisting CVD between the
olmesartan and placebo group. The patients with preexist-
ing CVD should be allocated evenly in each group if we
primarily analysed cardiovascular outcomes. Despite this
imbalance in CVD, it has not affected our analysis on
primary renal outcome. Second, cardiovascular outcome
was a composite of several events including HF and
peripheral arterial disease. Third, the study was underpow-
ered to make a confident statement of safety for cardiovas-
cular mortality as discussed above.
Conclusion
In type 2 diabetic patients with overt nephropathy and renal
insufficiency receiving concomitant antihypertensive agents
including ACEI, treatment with olmesartan reduced pro-
teinuria and BP but did not further improve renal outcomes.
Further study is recommended to confirm the beneficial
effect of olmesartan on cardiovascular outcome.
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